Time: 2024-07-17
A new vaccine program is set to be launched in Wales to protect against respiratory syncytial virus ( RSV ) , a common respiratory infection that poses a risk to babies and older adults . The vaccine will be offered to pregnant women from 28 weeks and individuals aged 75 to 79 years old . RSV can lead to severe complications like bronchiolitis and pneumonia , with over a thousand babies in Wales being hospitalized annually due to the infection . The aim of the program is to prevent illness and reduce the likelihood of severe infection , ultimately keeping individuals out of hospitals and reducing the burden on healthcare services.
The Advisory Committee on Immunization Practices ( ACIP ) recently met to discuss new vaccines and recommendations for various respiratory illnesses , including RSV , flu , COVID , and a new pneumococcal vaccine . The ACIP provided detailed recommendations regarding RSV vaccines for adults over 60 and issued specific guidelines based on age and risk factors . The committee highlighted the importance of timely vaccination , particularly for individuals with underlying health conditions that put them at a higher risk of severe RSV infection.
As the COVID landscape continues to evolve , ACIP has recommended a dose of the updated 2024 - 2025 COVID vaccine for individuals aged 6 months and older . The new vaccine formula is expected to provide an additional boost to immunity , especially with the emergence of new variants . The ACIP emphasized the importance of vaccination for older adults and young children , who are among the most vulnerable populations . Despite improvements in vaccine accessibility , uptake rates for the updated COVID vaccine remain suboptimal , stressing the need for increased awareness and education on the benefits of vaccination.
The approval of a new pneumococcal vaccine , PCV21 , offers an additional option for adults aged 18 and older to prevent invasive pneumococcal disease and pneumonia . The vaccine , known as Capvaxive , covers a broader range of serotypes compared to previous versions , providing enhanced protection against pneumococcal infections . Additionally , changes to the seasonal flu vaccine , including a shift to a trivalent formula and off - label recommendations for high - risk groups like solid organ transplant recipients , aim to enhance flu protection and reduce the spread of influenza viruses in the community . Overall , these advancements in vaccine technology and recommendations play a crucial role in safeguarding public health and preventing the spread of infectious diseases.
Business
